
FDA Submission Strategy & Regulatory Narrative Builder
Build FDA submissions faster with AI-powered regulatory strategy
What You Can Do
Analyze FDA guidance documents, structure regulatory narratives for IND/NDA/BLA submissions, and develop data-driven submission strategies aligned with current regulatory expectations. Claude identifies compliance gaps, predicts likely deficiency questions, and delivers submission-ready content formatted according to FDA conventions.
Features
Parse complex FDA guidance documents and extract key regulatory expectations, data requirements, and submission standards specific to your program.
Build comprehensive narratives addressing nonclinical overview, clinical safety/efficacy, CMC, and previous human experience in FDA-compliant format.
Map optimal regulatory pathways (505(b)(1), 505(b)(2), accelerated approval) and create milestone-driven timelines based on your development stage.
Review draft submissions and flag potential deficiency areas likely to trigger FDA Refuse to File (RTF) or Complete Response Letter (CRL) decisions.
Rank regulatory risks by likelihood and business impact, focusing your team's efforts on the highest-consequence gaps first.
Anticipate FDA questions and develop response strategies proactively, reducing back-and-forth cycles during review.
Generate talking points and anticipated questions for Type B/C meetings with FDA, ensuring your team alignment before official meetings.
Example Output
Example 1: Regulatory Narrative Outline (IND Application)
Nonclinical Overview
- Pharmacology: Mechanism in [INDICATION]; receptor binding affinity data from [STUDY]
- Toxicology: GLP studies completed at 0, 10, 50, 250 mg/kg; MTD established at 250 mg/kg
- Key Gaps: Additional juvenile toxicology likely required given pediatric indication
Clinical Overview
- Previous Human Experience: Phase 1 in 120 healthy volunteers; PK/PD data supports proposed Phase 2 dosing
- Proposed Phase 2: 250 patient, 12-week study in [INDICATION]; endpoints align with FDA guidance
Example 2: Deficiency Risk Assessment Table
| Deficiency Area | Likelihood | Severity | Mitigation |
|---|---|---|---|
| CMC: Manufacturing scale-up data | High | Critical | Provide 3-batch consistency data before submission |
| Clinical: Cardiovascular safety | Medium | Major | Add ECG monitoring in Phase 2 protocol |
| Nonclinical: Additional species data | Low | Minor | Reference comparable mechanism data |
Example 3: Submission Timeline
- Q3 2026: Submit IND, Type B meeting request
- Q4 2026: FDA IND response; initiate Phase 2 manufacturing scale-up
- Q2 2027: Complete Phase 2 enrollment; Type C meeting on NDA strategy
- Q4 2027: File NDA (target)
- Q4 2028: Potential approval (20-month FDA standard review)
What's Included
- FDA Guidance Navigator: Framework for extracting regulatory expectations from official FDA guidance, including identification of critical data elements and approval pathway prerequisites.
- Regulatory Narrative Templates: Structured outlines for IND, NDA, and BLA narratives following CBER/CDER format conventions, pre-formatted for sections 2-8 of CMC-P submission modules.
- Data Gap & Risk Analyzer: Systematic method to identify missing data, rank compliance risks by likelihood and business impact, and recommend priority study or data collection.
- Submission Strategy Planner: Decision tree for selecting optimal regulatory pathway (standard review, accelerated approval, breakthrough designation) and multi-year milestone planning.
- Compliance Checklist Generator: Customizable checklists for IND/NDA/BLA components, updated to reflect current FDA expectations and recent guidance changes.
- Meeting Preparation Toolkit: Talking point templates and anticipated question frameworks for Type B/C pre-submission meetings, with response strategies.
Who It's For
- Regulatory Affairs Specialists
- Pharmaceutical Program Managers
- Clinical Development Directors
- Biotech Startup Founders & Operations Leaders
- Quality Assurance & CMC Directors
Best For
- IND application development and strategy
- NDA/BLA submission planning and narrative structuring
- Pre-submission meeting preparation and strategy alignment
- FDA guidance interpretation and compliance gap analysis
- Regulatory risk assessment and deficiency mitigation planning






